Safety and Tolerability of Weekly Semaglutide Injections in Adults with Cocaine Use Disorder, With and Without HIV

What this Trial Is About

This research evaluates the safety and tolerability of semaglutide in adults with cocaine use disorder, including those with and without HIV. The study also aims to see if semaglutide affects cocaine use, craving, risk behaviors, mood, and certain health biomarkers. This is a 16-week, double-blind, placebo-controlled pilot study with dose escalation for semaglutide. Participants are randomly assigned to receive either weekly injections of semaglutide or a placebo. The semaglutide dose begins at 0.25 mg and may increase to a maximum of 2.0 mg if tolerated. Study visits include weekly injections and biweekly lab work, assessments, and surveys. Participants who agree may also complete optional MRI scans before starting treatment and near the study end. During the study, participants will have regular medical exams, clinical assessments, and lab tests to monitor health and drug effects. Researchers will track safety, tolerability, cocaine use patterns, mood changes, body composition, inflammatory and heart-related biomarkers, and brain function. The entire study duration is 16 weeks, with a final assessment at the end.

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV